◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Piramal Pharma Limited (PPLPHARMA)
来自官方财务报表的收入、利润与现金流历史。
Healthcare · 华尔街（美国） · 最近更新： 2026-09-20
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities.
关键数据
- 市值: ₹276 billion
- 收入（截至 2026-03-31 财年）: ₹87.6B
- 净利润: (₹3.3B)
- 毛利率: 59.1%
- 净利率: -3.7%
查看交互式图表与完整报表 →
年度利润表
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|
| 总收入 | ₹87.6B | ₹90.6B | ₹81.1B | ₹70.3B | — |
| 毛利 | ₹51.8B | ₹54.9B | ₹48.5B | ₹40.3B | — |
| 营业利润（EBIT） | ₹1.5B | ₹6.8B | ₹4.6B | (₹480M) | — |
| 净利 | (₹3.3B) | ₹911M | ₹178M | (₹1.9B) | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 PPLPHARMA 交互式查看器。 /companies/us/PPLPHARMA
类似公司
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.